Abstract: The present application relates to a variant of ornithine decarboxylase or protein, a polynucleotide encoding the same, a microorganism containing the same, and a method for producing putrescine using the same. The present invention achieves effects of increasing putrescine productivity, production efficiency or production selectivity, suppressing side reactions, and saving the cost involved in purifying putrescine.

Abstract: The present invention relates to a method of co-incubating multiple cells. According to the present invention, an interaction between the multiple cells is facilitated without causing cytotoxicity, and a single cell can be separated without damage to the cells. Therefore, the present invention can be applied to a study of regeneration on various types of tissue cells.

Abstract: The present invention relates to a biopolymer-based hydrogel as a functional biomaterial produced by crosslinking in the presence of a photopolymerization initiator. The hydrogel of the present invention is elastic so as to be adapted to various shapes in both in vivo and in vitro applications. It is biocompatible, achieving maximum effects on wound healing as wound dressing and tissue adhesion preventing material. The present invention also relates to a method for producing the biocompatible hydrogel.

Abstract: A composition contains, as an effective component, theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The composition has an excellent stability and provides wrinkle-reducing or skin elasticity-enhancing benefits, and skin-brightening benefits by containing theasinensin A, an enantiomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, as an effective component.

Abstract: The present invention relates to a cross-linked material having adhesion prepared by using tyrosinase derived from Burkholderia, preparation method thereof and application thereof, and specifically relates to the hydrogel composition having adhesiveness. The hydrogel composition having adhesiveness of the present invention is injectable through an injection or spraying, and can be used in 3D printing or preparation of adhesive hydrogel medical film, etc.

Abstract: The present invention relates to a method for producing a lysine carboxylase mutant strain, characteristics of the mutant strain, a gene encoding the lysine decarboxylase mutant strain, and a method for producing cadaverine using the same. The present invention provides lysine decarboxylase derived from E. coli improved through a protein engineering variation. In addition, the lysine decarboxylase mutant strain of the present invention increases activity, pH stability, and thermal stability at the time of producing cadaverine, thereby reducing production costs, through increasing a yield and productivity.

Abstract: The present invention relates to a biopolymer-based hydrogel as a functional biomaterial produced by crosslinking in the presence of a photopolymerization initiator. The hydrogel of the present invention is elastic so as to be adapted to various shapes in both in vivo and in vitro applications. It is biocompatible, achieving maximum effects on wound healing as wound dressing and tissue adhesion preventing material. The present invention also relates to a method for producing the biocompatible hydrogel.

Abstract: The present invention provides an ?-1,3 fucosyltransferase mutant having an increased expression level of soluble protein and increased activity, a DNA encoding the ?-1,3 fucosyltransferase mutant, a recombinant vector comprising the DNA encoding the ?-1,3 fucosyltransferase mutant, a host cell transformed with the recombinant DNA vector, an extract of the host cell, a method for producing 3-fucosyloligosaccharide, a method for preparing an ?-1,3 fucosyltransferase mutant, and a method for screening an ?-1,3 fucosyltransferase mutant. The ?-1,3 fucosyltransferase mutant of the present invention has a significantly increased soluble protein expression level and activity.

Abstract: The present invention relates to a method for producing a lysine carboxylase mutant strain, characteristics of the mutant strain, a gene encoding the lysine decarboxylase mutant strain, and a method for producing cadaverine using the same. The present invention provides lysine decarboxylase derived from E. coli improved through a protein engineering variation. In addition, the lysine decarboxylase mutant strain of the present invention increases activity, pH stability, and thermal stability at the time of producing cadaverine, thereby reducing production costs, through increasing a yield and productivity.

Abstract: The present invention relates to a pharmaceutical composition and a cosmetic composition, which contain, as an active ingredient, a novel pseudo compound having similar structural characteristics to natural ceramide 1, or a pharmaceutically acceptable salt or solvate thereof, and the composition containing the compound of the present invention as an active ingredient has an excellent effect of enhancing a skin barrier function, thereby exhibiting an effect of alleviating inflammatory skin diseases, and has an excellent skin barrier improving function and an excellent skin moisturization enhancing effect.

Abstract: The present invention provides an ?-1,3 fucosyltransferase mutant having an increased expression level of soluble protein and increased activity, a DNA encoding the ?-1,3 fucosyltransferase mutant, a recombinant vector comprising the DNA encoding the ?-1,3 fucosyltransferase mutant, a host cell transformed with the recombinant DNA vector, an extract of the host cell, a method for producing 3-fucosyloligosaccharide, a method for preparing an ?-1,3 fucosyltransferase mutant, and a method for screening an ?-1,3 fucosyltransferase mutant. The ?-1,3 fucosyltransferase mutant of the present invention has a significantly increased soluble protein expression level and activity.

Abstract: The present invention relates to a method for preparing a sialic acid derivative characterized by performing both of a process for preparing CMP-N-acetylneuraminic acid using N-acetyl-D-glucosamine and a process for preparing the sialic acid (neuraminic acid) derivative that combines a sialic acid with a galactose derivative or a lactose derivative, together, in one reactor. According to the method for preparing a sialic acid derivative of the present invention, expensive cytidine 5?-monophosphate (CMP) is capable of being recycled in a reactor, such that an amount of the CMP introduced into the reactor may be reduced, and the sialic acid derivative is capable of being prepared at a significantly high efficiency by using cheap N-acetyl-D-glucosamine, and pyruvate as substrates.

Abstract: The present invention relates to a pharmaceutical composition and a cosmetic composition, which contain, as an active ingredient, a novel pseudo compound having similar structural characteristics to natural ceramide 1, or a pharmaceutically acceptable salt or solvate thereof, and the composition containing the compound of the present invention as an active ingredient has an excellent effect of enhancing a skin barrier function, thereby exhibiting an effect of alleviating inflammatory skin diseases, and has an excellent skin barrier improving function and an excellent skin moisturization enhancing effect.

Abstract: The present invention relates to the novel Rhizobium sp. GIN611 KCTC11708BP or to cell extracts thereof, to a novel oxidoreductase which exhibits a glycolytic activity, to a gene encoding the oxidoreductase, to a recombinant strain comprising recombinant vector proteins or to an expression vector encoding recombinant proteins, and to a method for the glycolysis of natural products using same as a biocatalyst. The present invention also relates to a method for producing aglycones from a variety of natural products using same. The novel oxidoreductase separated from the novel microorganism of the present invention does not belong to a glucosidase group but belongs to an oxidoreductase group, and has a glycolytic activity for natural products. The novel oxidoreductase oxidizes the sugar in the aglycones of natural products, thereby producing a variety of aglycones.

Abstract: The present invention relates to a method for preparing a sialic acid derivative characterized by performing both of a process for preparing CMP-N-acetylneuraminic acid using N-acetyl-D-glucosamine and a process for preparing the sialic acid (neuraminic acid) derivative that combines a sialic acid with a galactose derivative or a lactose derivative, together, in one reactor. According to the method for preparing a sialic acid derivative of the present invention, expensive cytidine 5?-monophosphate (CMP) is capable of being recycled in a reactor, such that an amount of the CMP introduced into the reactor may be reduced, and the sialic acid derivative is capable of being prepared at a significantly high efficiency by using cheap N-acetyl-D-glucosamine, and pyruvate as substrates.

Abstract: The present invention relates to the novel Rhizobium sp. GIN611 KCTC11708BP or to cell extracts thereof, to a novel oxidoreductase which exhibits a glycolytic activity, to a gene encoding the oxidoreductase, to a recombinant strain comprising recombinant vector proteins or to an expression vector encoding recombinant proteins, and to a method for the glycolysis of natural products using same as a biocatalyst. The present invention also relates to a method for producing aglycones from a variety of natural products using same. The novel oxidoreductase separated from the novel microorganism of the present invention does not belong to a glucosidase group but belongs to an oxidoreductase group, and has a glycolytic activity for natural products. The novel oxidoreductase oxidizes the sugar in the aglycones of natural products, thereby producing a variety of aglycones.

Abstract: The present invention relates to a novel N-acetylglucosamine-2-epimerase and a method for preparing CMP-N-acetylneuraminic acid, more specifically, relates to a N-acetylglucosamine-2-epimerase derived from Bacteroides fragilis NCTC 9343, and a method for preparing CMP-N-acetylneuraminic acid using said N-acetylglucosamine-2-epimerase. According to the present invention, CMP-N-acetylneuraminic acid can be produced economically in a large amount through a one-step reaction using cytidine monophosphate and N-acetyl-D-glucosamine which are inexpensive substrates.

Abstract: The present invention relates to the novel Rhizobium sp. GIN611 KCTC11708BP or to cell extracts thereof, to a novel oxidoreductase which exhibits a glycolytic activity, to a gene encoding the oxidoreductase, to a recombinant strain comprising recombinant vector proteins or to an expression vector encoding recombinant proteins, and to a method for the glycolysis of natural products using same as a biocatalyst. The present invention also relates to a method for producing aglycones from a variety of natural products using same. The novel oxidoreductase separated from the novel microorganism of the present invention does not belong to a glucosidase group but belongs to an oxidoreductase group, and has a glycolytic activity for natural products. The novel oxidoreductase oxidizes the sugar in the aglycones of natural products, thereby producing a variety of aglycones.

Abstract: A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used to prevent and treat inflammatory diseases, and the LTA-derived glycolipid can be also used as the vaccine adjuvant.

Abstract: The present invention relates to a novel N-acetylglucosamine-2-epimerase and a method for preparing CMP-N-acetylneuraminic acid, more specifically, relates to a N-acetylglucosamine-2-epimerase derived from Bacteroides fragilis NCTC 9343, and a method for preparing CMP-N-acetylneuraminic acid using said N-acetylglucosamine-2-epimerase. According to the present invention, CMP-N-acetylneuraminic acid can be produced economically in a large amount through a one-step reaction using cytidine monophosphate and N-acetyl-D-glucosamine which are inexpensive substrates.